| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 3.4% | Vertical Research | → $110 | Initiates Coverage On | → Hold |
| 09/28/2023 | 10.92% | Deutsche Bank | → $118 | Initiates Coverage On | → Buy |
| 07/19/2023 | -5.06% | Stifel | $87 → $101 | Maintains | Buy |
| 05/12/2023 | -13.52% | DA Davidson | $90 → $92 | Maintains | Buy |
| 04/05/2023 | -22.92% | UBS | $120 → $82 | Maintains | Neutral |
| 03/24/2023 | 12.8% | UBS | $132 → $120 | Downgrades | Buy → Neutral |
| 12/12/2022 | 21.26% | Morgan Stanley | $116 → $129 | Upgrades | Equal-Weight → Overweight |
| 10/11/2022 | 13.74% | Stifel | $123 → $121 | Maintains | Buy |
| 07/28/2022 | 17.5% | UBS | $130 → $125 | Maintains | Buy |
| 01/31/2022 | 9.04% | Morgan Stanley | $111 → $116 | Maintains | Equal-Weight |
| 12/03/2021 | 4.34% | Morgan Stanley | → $111 | Initiates Coverage On | → Equal-Weight |
| 06/15/2021 | 3.4% | DA Davidson | → $110 | Upgrades | Neutral → Buy |
| 03/08/2021 | -6% | Canaccord Genuity | $96 → $100 | Maintains | Buy |
| 02/26/2021 | -9.76% | Canaccord Genuity | $86 → $96 | Maintains | Buy |
| 01/27/2021 | -19.16% | Canaccord Genuity | $82 → $86 | Maintains | Buy |
| 01/07/2021 | -24.8% | DA Davidson | $75 → $80 | Downgrades | Buy → Neutral |
| 10/28/2020 | -31.38% | Stifel | $72 → $73 | Maintains | Buy |
| 06/16/2020 | -37.96% | Canaccord Genuity | $62 → $66 | Upgrades | Hold → Buy |
| 04/29/2020 | -45.48% | CFRA | $89 → $58 | Reiterates | → Hold |
| 04/07/2020 | -33.26% | Stifel | $105 → $71 | Maintains | Buy |
| 01/29/2020 | -17.28% | Canaccord Genuity | $85 → $88 | Maintains | Hold |
| 01/29/2020 | -1.3% | Stifel | $96 → $105 | Maintains | Buy |
| 01/29/2020 | -19.16% | Buckingham Research | $79 → $86 | Upgrades | Neutral → Buy |
| 10/30/2019 | -25.74% | Buckingham Research | $102 → $79 | Downgrades | Buy → Neutral |
| 10/30/2019 | -20.1% | Canaccord Genuity | $105 → $85 | Downgrades | Buy → Hold |
| 10/30/2019 | — | Vertical Research | Downgrades | Buy → Hold | |
| 07/24/2019 | -4.12% | Buckingham Research | $97 → $102 | Maintains | Buy |
| 07/24/2019 | 0.58% | DA Davidson | $105 → $107 | Maintains | Buy |
| 05/29/2019 | -9.76% | Buckingham Research | $102 → $96 | Maintains | Buy |
| 05/14/2019 | -4.12% | Buckingham Research | $101 → $102 | Maintains | Buy |
| 04/11/2019 | -6% | UBS | $90 → $100 | Maintains | Buy |
| 01/29/2019 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 12/11/2018 | -12.58% | Buckingham Research | → $93 | Initiates Coverage On | → Buy |
What is the target price for Crane (CR)?
The latest price target for Crane (NYSE: CR) was reported by Vertical Research on November 20, 2023. The analyst firm set a price target for $110.00 expecting CR to rise to within 12 months (a possible 3.40% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crane (CR)?
The latest analyst rating for Crane (NYSE: CR) was provided by Vertical Research, and Crane initiated their hold rating.
When is the next analyst rating going to be posted or updated for Crane (CR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crane, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crane was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Crane (CR) correct?
While ratings are subjective and will change, the latest Crane (CR) rating was a initiated with a price target of $0.00 to $110.00. The current price Crane (CR) is trading at is $106.39, which is within the analyst's predicted range.